Medical

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

Every year, 40000 women die of breast cancer in the United States alone. When cancers are discovered at an early stage, they can often be cured. Mammography is the best alternative diagnostic method, but this method also has shortcomings. It often results in false positive results, leading to unnecessary surgery.

Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.

Latest real-world data published, providing real evidence of the effectiveness of Azulfidine in patients with COVID-19

The FDA granted Fast Track designation to a new drug, IK-175, in combination with nabumab for the treatment of advanced uroepithelial carcinoma, after preliminary trial data showed encouraging and durable anti-tumor activity with a favorable safety profile.

DZD1516 is a reversible, selective HER2-targeting agent with full blood-brain barrier penetration. It has demonstrated good therapeutic response in phase I studies in patients with metastatic HER2-positive breast cancer, including breast cancer patients with central nervous system metastases.

A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.

The European Union has approved the marketing of the new treatment Opdualag for the treatment of melanoma patients. New data demonstrates that the treatment resulted in the complete disappearance of tumours in 16.3% of patients, a significant reduction in tumours in 26.8% and stable disease without further progression in 18.2% of patients, giving an efficiency rate of 61.3%.

Alveolar rhabdomyosarcoma is a rare but very deadly childhood tumour, and for more than 40 years there have been no new advances in the treatment of this disease. Recently, a study led by Professor Anton Henssen of the Charité University of Berlin has identified a promising new treatment for the disease.

A cutting-edge study from the University of California, San Francisco, recently showed that researchers have been able to make immune cells, which already recognize cancer cells, more powerful and durable through CRISPR gene editing tools, promising to become tireless, cold-blooded "cancer killers"!